We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

174 hedge funds and large institutions have $1.86B invested in Celldex Therapeutics in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 66 increasing their positions, 48 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more call options, than puts

Call options by funds: $24.9M | Put options by funds: $17.1M

38% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 48

2.75% more ownership

Funds ownership: 108.33% → 111.07% (+2.7%)

6% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 36

1% less funds holding

Funds holding: 176 → 174 (-2)

24% less capital invested

Capital invested by funds: $2.44B → $1.86B (-$579M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
174
Holders Change
-2
Holders Change %
-1.14%
% of All Funds
2.29%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
34
Increased
66
Reduced
48
Closed
36
Calls
$24.9M
Puts
$17.1M
Net Calls
+$7.83M
Net Calls Change
-$17.5M

Top Buyers

1
JFG
Jefferies Financial Group
New York
+$64.4M
2
KCM
Kynam Capital Management
New Jersey
+$43.6M
3
DTC
Deep Track Capital
Connecticut
+$41.8M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$25.7M
5
Morgan Stanley
Morgan Stanley
New York
+$24.7M

Top Sellers

1
CC
Commodore Capital
New York
-$55M
2
Jennison Associates
Jennison Associates
New York
-$45M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$31.7M
4
PCH
Polar Capital Holdings
United Kingdom
-$31.4M
5
LGM
Logos Global Management
California
-$30.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$15.1M +$948K +34,885 +6%
Charles Schwab
27
Charles Schwab
California
$13.8M +$149K +5,474 +1%
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$13.1M -$8.33M -306,777 -37%
5VM
29
5AM Venture Management
California
$12.6M – – –
SFM
30
Sphera Funds Management
Israel
$12M +$1.49M +55,000 +13%
Fisher Asset Management
31
Fisher Asset Management
Washington
$11.4M +$2.12M +78,145 +21%
UBS Group
32
UBS Group
Switzerland
$9.85M +$6.06M +223,200 +134%
VPC
33
Vestal Point Capital
New York
$7.71M +$8.29M +305,000 New
CM
34
Crestline Management
Texas
$7.46M +$4.28M +157,366 +114%
N
35
Nuveen
North Carolina
$7.29M -$2.04M -75,257 -21%
SCM
36
Silverarc Capital Management
Massachusetts
$6.69M +$3.25M +119,560 +82%
BBA
37
Baker Bros. Advisors
New York
$6.26M – – –
TCMG
38
TSP Capital Management Group
New Jersey
$5.64M -$665K -24,477 -10%
TAM
39
TFG Asset Management
Cayman Islands
$4.85M +$5.22M +192,000 New
Axa
40
Axa
France
$4.68M -$7.99K -294 -0.2%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$4.59M +$11.1K +410 +0.2%
CSS
42
Cubist Systematic Strategies
Connecticut
$3.9M +$4.2M +154,512 New
Rafferty Asset Management
43
Rafferty Asset Management
New York
$3.85M +$1.67M +61,464 +68%
TD Asset Management
44
TD Asset Management
Ontario, Canada
$3.64M -$549K -20,200 -12%
Barclays
45
Barclays
United Kingdom
$3.61M +$341K +12,533 +10%
RAM
46
Readystate Asset Management
Illinois
$3.59M -$1.02M -37,480 -21%
PAMP
47
Polar Asset Management Partners
Ontario, Canada
$3.48M +$3.47M +127,850 +1,318%
Renaissance Technologies
48
Renaissance Technologies
New York
$3.45M +$3.71M +136,588 New
Deutsche Bank
49
Deutsche Bank
Germany
$3.07M +$2.23M +82,042 +208%
MCP
50
Mirador Capital Partners
California
$3.02M +$90.9K +3,345 +3%
1
2
3 4 5

CLDX Hedge Fund Activity: Q4 2024 in Review

174 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2024, worth a combined $1.86B — down 24% from $2.44B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CLDX and 34 opened new positions — a net loss of 2 holders — while 48 trimmed existing stakes and 66 added.

The largest buyer was Jefferies Financial Group, adding an estimated $64.4M. The largest seller was Commodore Capital, exiting entirely with an estimated $55M sold.

  • 174 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2024, down from 176 in Q3 2024.
  • Funds reported $1.86B of Celldex Therapeutics stock for Q4 2024, down 24% quarter-over-quarter.
  • 34 funds opened new Celldex Therapeutics positions in Q4 2024 and 36 closed out, a net change of -2 holders.
  • The largest Celldex Therapeutics buyer in Q4 2024 was Jefferies Financial Group, an estimated $64.4M added.
  • The largest Celldex Therapeutics seller in Q4 2024 was Commodore Capital, an estimated $55M sold.

Based on aggregated 13F filings for Q4 2024.